Erectile Dysfunction Clinical Trial
Official title:
Low Intensity Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction- 4 Arms
Low intensity shock waves(LISW) have been proven in animal studies to induce local growth of new blood vessels. The investigators hypothesized that LISW therapy could improve the symptoms of patients with erectile dysfunction resulting from a problem of blood supply who respond to oral therapy (PDE-5 inhibitors). The current study will check 4 different arm.
At the first meeting the patient will receive a full explanation of the study, the potential
efficacy and risks. After that the patient will be asked to sign an informed consent form,
and will be asked about general medical condition and any problems related to sexual
dysfunction. Than the patient's sexual function will be assessed by sexual function
questionnaires. The criteria for inclusion and exclusion will be reviewed, as well as
physical examination. During the visit, the patient will be assigned to one arm of the study
(random), and by the arm he belongs he will receive an explanation about this procedure.
Then shall obtain reporting sexual encounter diaries (SEP) and will be asked to avoid using
PDE5i's for a month (washout), then it would be the first visit. At the first visit (Visit
1) The patient will be questioning the sexual function questionnaires without PDE5i's and
will pass examination performance Endothelial - FMD, the test takes about 10 minutes, it is
not an invasive test (not involved in inserting an instrument or any medication) and is
painless. The patient may be asked to also undergo Doppler ultrasound. At the end of the
visit 1 the patient will begin treatment series and will continue to study under the arm
belongs, as described: 1.Series of 12 treatments, in which the subject will be treated twice
a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks,
and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
2.Series of 12 treatments, in which the subject will be treated twice a week for 6
consecutive weeks, without intermission. 3.Series of 8 treatments, in which the subject will
be treated twice a week for two weeks (4 treatments), then would be discontinuation of the
study for 3 weeks, and at the end of this period will be treated twice a week for two weeks
(4 treatments). 4.Series of 6 treatments, in which the subject will be treated once a week
for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at
the end of this period will be treated once a week for 3 weeks (3 treatments).
Four weeks after the treatment series ends the patient will come for another visit will be
asked to fill in questionnaires and perform the FMD test again.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
| Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
| Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
| Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
| Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
| Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
| Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
| Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
| Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
| Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
| Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
| Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
| Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
| Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
| Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 |